AAP
VIR icon

Arax Advisory Partners’s Vir Biotechnology VIR Stock Holding History

Arax Advisory Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.5K Buy
9,669
+8,095
+514% +$77K ﹤0.01% 2741
2026
Q1 		$14.1K Buy
1,574
+889
+130% +$7.08K ﹤0.01% 2268
2025
Q4 		$4.13K Sell
685
-1,072
-61% -$6.38K ﹤0.01% 2952
2025
Q3 		$10K Buy
1,757
+1,363
+346% +$6.97K ﹤0.01% 2598
2025
Q2 		$1.99K Buy
394
+276
+234% +$1.48K ﹤0.01% 2567
2025
Q1 		$765 Buy
+118
New +$1.05K ﹤0.01% 2403

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arax Advisory Partners's VIR Position: Q2 2026 in Review

Arax Advisory Partners increased its Vir Biotechnology (VIR) stake by 514% in Q2 2026, buying an estimated $77K and bringing the position to 9,669 shares worth $98.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2741.

Arax Advisory Partners first reported a position in VIR in Q1 2025 and has held it in 6 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Arax Advisory Partners held 9,669 shares of Vir Biotechnology worth $98.5K as of Q2 2026.
  • Arax Advisory Partners bought 8,095 Vir Biotechnology shares in Q2 2026, an estimated $77K.
  • Vir Biotechnology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2741 holding.
  • Arax Advisory Partners first reported a position in Vir Biotechnology in Q1 2025 and has held it in 6 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.